Carl Byrnes
Stock Analyst at Northland Securities
(0.27)
# 4,312
Out of 4,531 analysts
284
Total ratings
37.2%
Success rate
-3.9%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings | Maintained: Buy | $7.5 | $2.38 | +215.13% | 3 | Apr 24, 2026 | |
| MDXG MiMedx Group | Maintained: Buy | $10 → $6 | $4.30 | +39.53% | 27 | Apr 17, 2026 | |
| SPRY ARS Pharmaceuticals | Maintained: Buy | $25 | $7.00 | +257.14% | 2 | Apr 15, 2026 | |
| RCEL AVITA Medical | Maintained: Buy | $10 | $5.10 | +96.08% | 2 | Mar 26, 2026 | |
| BLFS BioLife Solutions | Reiterated: Buy | $34 | $29.15 | +16.64% | 37 | Mar 24, 2026 | |
| TLSI TriSalus Life Sciences | Rated: Buy | $13 → $8 | $4.29 | +86.48% | 5 | Mar 23, 2026 | |
| MDAI Spectral AI | Maintained: Buy | $6 | $1.67 | +259.28% | 12 | Mar 19, 2026 | |
| SNWV SANUWAVE Health | Maintained: Buy | $55 | $6.39 | +760.72% | 4 | Mar 16, 2026 | |
| INDV Indivior Pharmaceuticals | Maintained: Buy | $50 | $40.54 | +23.33% | 12 | Feb 27, 2026 | |
| BWAY BrainsWay | Maintained: Buy | $12 → $15 | $15.73 | -4.64% | 14 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.46 | +189.02% | 18 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $4 | $0.4707 | +749.80% | 39 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.7016 | +612.66% | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $2 → $1.25 | $13.94 | n/a | 12 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $1.72 | n/a | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $8 → $1 | $0.0001 | n/a | 24 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $2 | $0.0001 | n/a | 24 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 → $2 | $32.88 | n/a | 30 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.15 | n/a | 12 | May 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $45 | $60.74 | n/a | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $14.92 | n/a | 1 | Oct 22, 2018 |
Connect Biopharma Holdings
Apr 24, 2026
Maintained: Buy
Price Target: $7.5
Current: $2.38
Upside: +215.13%
MiMedx Group
Apr 17, 2026
Maintained: Buy
Price Target: $10 → $6
Current: $4.30
Upside: +39.53%
ARS Pharmaceuticals
Apr 15, 2026
Maintained: Buy
Price Target: $25
Current: $7.00
Upside: +257.14%
AVITA Medical
Mar 26, 2026
Maintained: Buy
Price Target: $10
Current: $5.10
Upside: +96.08%
BioLife Solutions
Mar 24, 2026
Reiterated: Buy
Price Target: $34
Current: $29.15
Upside: +16.64%
TriSalus Life Sciences
Mar 23, 2026
Rated: Buy
Price Target: $13 → $8
Current: $4.29
Upside: +86.48%
Spectral AI
Mar 19, 2026
Maintained: Buy
Price Target: $6
Current: $1.67
Upside: +259.28%
SANUWAVE Health
Mar 16, 2026
Maintained: Buy
Price Target: $55
Current: $6.39
Upside: +760.72%
Indivior Pharmaceuticals
Feb 27, 2026
Maintained: Buy
Price Target: $50
Current: $40.54
Upside: +23.33%
BrainsWay
Jan 22, 2026
Maintained: Buy
Price Target: $12 → $15
Current: $15.73
Upside: -4.64%
Nov 14, 2025
Maintained: Buy
Price Target: $10
Current: $3.46
Upside: +189.02%
Nov 5, 2025
Reiterated: Buy
Price Target: $9 → $4
Current: $0.4707
Upside: +749.80%
Aug 28, 2025
Maintained: Buy
Price Target: $5
Current: $0.7016
Upside: +612.66%
Jul 19, 2023
Rated: Hold
Price Target: $2 → $1.25
Current: $13.94
Upside: n/a
May 22, 2023
Initiated Coverage: Buy
Price Target: $8
Current: $1.72
Upside: n/a
Jan 6, 2023
Downgraded: Sell
Price Target: $8 → $1
Current: $0.0001
Upside: n/a
Nov 23, 2022
Maintained: Buy
Price Target: $10 → $2
Current: $0.0001
Upside: n/a
Aug 17, 2022
Maintained: Buy
Price Target: $4 → $2
Current: $32.88
Upside: n/a
May 14, 2020
Rated: Hold
Price Target: n/a
Current: $2.15
Upside: n/a
Oct 22, 2018
Initiated Coverage: Buy
Price Target: $45
Current: $60.74
Upside: n/a
Oct 22, 2018
Initiated Coverage: Buy
Price Target: n/a
Current: $14.92
Upside: n/a